Glycomimetics Stock Price, News & Analysis

GlycoMimetics, Inc. (Nasdaq: GLYC) has historically been described as a late clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases. According to company disclosures, its scientific approach is based on understanding the role that carbohydrates play in cell recognition and using this knowledge to design small molecule drugs, known as glycomimetics, that alter carbohydrate-mediated recognition in diverse disease states, including cancers and inflammation. The company has stated that its goal is to develop transformative therapies for diseases with high unmet medical need.

GlycoMimetics has reported that it is headquartered in Rockville, Maryland, in the BioHealth Capital Region. It has also noted that it is a public company traded on Nasdaq under the symbol GLYC. Over time, the company has characterized itself as a late clinical-stage biotechnology organization, reflecting its focus on advancing investigational drug candidates through clinical development rather than commercial-stage operations.

Scientific focus and technology platform

In its public communications, GlycoMimetics explains that its specialized chemistry platform is used to discover small molecule drugs called glycomimetics. These molecules are designed to interfere with carbohydrate-mediated recognition processes that play a role in diseases such as cancers and inflammatory conditions. The company highlights that its scientific approach is grounded in the role that carbohydrates play in cell recognition and in the bone marrow microenvironment.

GlycoMimetics has described uproleselan as an investigational, first-in-class E-selectin antagonist discovered and developed by the company. E-selectin is described as a leukocyte adhesion molecule constitutively expressed on endothelial cells of the vasculature and bone marrow. In AML, the company cites evidence that E-selectin–ligand interaction between endothelial cells in the protective niche of the bone marrow microenvironment and leukemic stem cells and blasts promotes leukemic cell survival and hides them from AML therapies. Uproleselan is described as being designed to disrupt E-selectin binding and prevent leukemic myeloid cells from using this protective niche.

The company has also described GMI-1687 as a highly potent E-selectin antagonist that is bioavailable after subcutaneous administration. GlycoMimetics has stated that this second-generation compound has potential application in oncology and inflammatory diseases, and that its initial clinical development has focused on sickle-cell disease (SCD). In its description, E-selectin is believed to play a major role in vaso-occlusive events, a group of acute complications associated with SCD. The company has indicated that administration of GMI-1687 by subcutaneous injection, if successfully developed in the clinic, may enable the study drug to be approved as a patient-controlled, point-of-care treatment option.

Clinical-stage pipeline and therapeutic areas

Public statements from GlycoMimetics emphasize its focus on AML and other cancers, as well as inflammatory diseases. The company has repeatedly described itself as a late clinical-stage biotechnology company and has referenced a pivotal Phase 3 study of uproleselan in relapsed/refractory AML, as well as an adaptive Phase 2/3 study of uproleselan in adults with newly diagnosed AML who are 60 years or older and fit for intensive chemotherapy. It has also referenced ongoing discussions with the National Cancer Institute (NCI) and the Alliance for Clinical Trials in Oncology regarding these studies.

In addition to oncology, GlycoMimetics has highlighted sickle-cell disease as an area of interest for GMI-1687, noting the potential role of E-selectin in vaso-occlusive events and related complications. Across its disclosures, the company consistently frames its research and development efforts around diseases with significant unmet medical need.

Corporate evolution and merger with Crescent Biopharma

According to an 8-K filing and related press releases, GlycoMimetics entered into an acquisition agreement with Crescent Biopharma, Inc., a privately held biotechnology company advancing a pipeline of oncology therapeutics designed to treat solid tumors. The companies disclosed that, upon completion of the transaction, the combined company planned to operate under the name Crescent Biopharma, Inc. A later press release reported that GlycoMimetics stockholders approved the proposed merger with Crescent and related proposals, including a reverse stock split of GlycoMimetics’ common stock.

An 8-K filed on June 18, 2025, states that on June 13, 2025, Crescent Biopharma, Inc., a Cayman Islands exempted company formerly known as GlycoMimetics, Inc., consummated the previously announced business combination. The filing explains that, after the completion of the merger and related steps, GlycoMimetics changed its name to Crescent Biopharma, Inc., and that ordinary shares with the trading symbol CBIO are listed on The Nasdaq Capital Market. The filing also describes how shares, options, restricted stock units, and pre-funded warrants of GlycoMimetics and Crescent were converted or assumed as part of the transaction.

As a result, the historical GLYC ticker now represents the pre-merger GlycoMimetics entity, while the post-merger company is named Crescent Biopharma, Inc. and trades under the symbol CBIO. The 8-K notes that, after giving effect to a pre-closing financing and the merger, GlycoMimetics securityholders owned a small percentage of the capital stock of the post-merger company on a fully diluted basis, with Crescent securityholders owning the remainder.

Status of GLYC as a historical symbol

Given the completed merger and name change described in the June 18, 2025 8-K, GLYC functions as a historical ticker symbol associated with GlycoMimetics prior to its combination with Crescent Biopharma. Investors researching GLYC are typically examining the legacy GlycoMimetics business, its glycobiology-based research platform, and its investigational candidates such as uproleselan and GMI-1687, as well as the sequence of events that led to the merger and transition to Crescent Biopharma, Inc. under the CBIO symbol.